The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, efficacy, and cost-effectiveness compared with reference drugs. Medscape News Europe
Aviceda Therapeutics Announces Phase 2b SIGLEC Results for AVD-104 in Geographic Atrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics (“the Company” or “Aviceda”), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b study evaluating…
Aviceda Therapeutics Announces Phase 2b SIGLEC Results for AVD-104 in Geographic Atrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics (“the Company” or “Aviceda”), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b study evaluating…
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,…
Uncategorized
Surgeon volunteer opportunities available in US
Click here to read the Cover Story, “Global ophthalmology: Learning through teaching.”Being a physician is a privilege because your skills can truly change a life.Restoring sight gives someone back their independence, and using your gifts in volunteer …
Uncategorized
VIDEO: Ixo-vec gene therapy shows safe results throughout 4-year study period
ORLANDO — In this video from the American Academy of Ophthalmology meeting, Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic, talks about findings from the phase 2 LUNA trial.Stewart told Healio that Ixo-vec (ixoberoge…